CEL-SCI Corporation CVM
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -73.76%
- 1 year
- -80.45%
- Market cap
- 24.27M
- EPS (ttm)
- -1.69
- Shares out
- 63.81M
- Forward P/E
- -1.59
- YTD return
- -73.76%
- 1-year return
- -80.45%
- Volume
- 27.79K
- Avg volume
- 191.33K
- Open
- 1.41
- Previous close
- 1.41
- Day's range
- 1.38 – 1.46
- 52-week range
- 0.89 – 7.80
- Beta
- 0.69
- Analysts
- Strong Buy
- Price target
- 7.73 (+460.4%)
- Earnings date
- Dec 27, 2024
5D -0.22 (-13.41%)
Key statistics
- Enterprise value
- 56.58M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -8.46M
- Total cash
- 435.78K
- Total debt
- 12.13M
- Return on equity
- -250.20%
- Short % of float
- 8.87%
- 50-day average
- 0.744
- 200-day average
- 1.20
Analyst view
Consensus: strong buy
- Target (low)
- 6.20
- Target (mean)
- 7.73
- Target (high)
- 10.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 27, 2024
Expected Dec 27, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 27, 2024 | Sep 1, 2024 | -0.11 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.13 | -0.14 | -0.01 | -7.69% |
| May 16, 2024 | Mar 1, 2024 | -0.14 | -0.14 | 0.00 | 0.00% |
| Feb 14, 2024 | Dec 1, 2023 | 0.00 | -0.14 | — | — |
| Dec 22, 2023 | Sep 1, 2023 | -0.16 | -0.16 | 0.00 | 0.00% |
| Aug 11, 2023 | Jun 1, 2023 | -0.17 | -0.19 | -0.02 | -11.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 12, 2023 | EF Hutton | reit | Buy | Buy |
| Mar 9, 2023 | EF Hutton | reit | — | Buy |
| Dec 29, 2022 | EF Hutton | main | — | Buy |
| Apr 7, 2022 | EF Hutton | init | — | Buy |
| Jan 13, 2020 | HC Wainwright & Co. | init | — | Buy |
| Feb 20, 2013 | Taglich Brothers | init | — | Speculative Buy |
About CEL-SCI Corporation
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cel-sci.com
News
CEL-SCI Presents New Pre-Surgical Data From Its Phase 3 Trial Of Multikine At World Congress; Locally Advanced Primary Tumor With No Detectable Lymph Node Involved; Tumor Proportion Score Less Than 10% 
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology 
CEL-SCI Q3 EPS $(0.47) Up From $(1.36) YoY 
CEL-SCI Reports Fiscal Third Quarter 2026 Results 
CEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral Oncology 
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study 
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - 12 Health Care Stocks Moving In Thursday's Intraday Session
Your note
Sign in to keep a note on CVM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KERSTEN GEERT R | Chief Executive Officer | Stock Award(Grant) | Sep 29, 2024 | 1,204,650 |
| PRICHEP PATRICIA B | Officer | Stock Award(Grant) | Sep 29, 2024 | 240,071 |
| TALOR EYAL | Officer | Stock Award(Grant) | Sep 29, 2024 | 118,596 |
| WATSON ROBERT EUGENE | Director | Purchase | May 7, 2024 | 24,431 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.78% | 2,411,246 | 1.68M | Sep 29, 2024 |
| Blackrock Inc. | 1.22% | 779,030 | 543.76K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.96% | 612,861 | 427.78K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.68% | 432,127 | 301.62K | Sep 29, 2024 |
| State Street Corporation | 0.30% | 193,507 | 135.07K | Sep 29, 2024 |
| Thoroughbred Financial Services LLC | 0.21% | 136,761 | 95.46K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.53% | 1,613,825 | 1.13M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.13% | 723,184 | 504.78K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 296,021 | 206.62K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.18% | 112,000 | 78.18K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 115,757 | 80.80K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 104,585 | 73.00K | Oct 30, 2024 |